Literature DB >> 22094117

Polymorphisms of genes involved in extracellular matrix remodeling and abdominal aortic aneurysm.

Claudia Saracini1, Paola Bolli, Elena Sticchi, Giovanni Pratesi, Raffaele Pulli, Francesco Sofi, Carlo Pratesi, Gian Franco Gensini, Rosanna Abbate, Betti Giusti.   

Abstract

BACKGROUND: Abdominal aortic aneurysm (AAA) has a multifactorial etiology and the relevance of genetic factors is getting increasing interest, in particular those related to the destructive remodeling of extracellular matrix.
METHODS: We performed a candidate gene association study of polymorphisms in genes coding matrix metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMPs), and elastin (ELN) in AAA. DNA samples from 423 AAA patients and 423 controls were genotyped for 12 polymorphisms in 10 genes: MMP1 (-1607G/GG), MMP2 (-735C/T; -1306C/T; -1575 G/A), MMP3 (5A/6A), MMP9 (-1562C/T), MMP10 (A180G), MMP-12 (-82A/G), MMP-13 (-77A/G), TIMP1 (C434T), TIMP3 (-1296T/C), and ELN (G1355A).
RESULTS: Genotype distribution was significantly different between patients and controls for the following polymorphisms: -1306C/T MMP2; 5A/6A MMP3; -77A/G MMP-13; G1355A ELN; and C434T TIMP1. In a multivariable logistic regression analysis adjusted for traditional cardiovascular risk factors and chronic obstructive pulmonary disease, -1306C/T MMP2 (odds ratios [OR] = 0.55 [95% confidence interval, CI .34-.85], P < .007) and G1355A ELN (OR = 0.64 ([95% CI .41-.99], P = .046) polymorphisms resulted in independent protective factors for abdominal aortic aneurysm (AAA), whereas 5A/6A MMP3 (OR = 1.82 [95% CI 1.04-3.12], P = .034) and -77 A/G MMP-13 (OR = 2.14 [95% CI 1.18-3.86], P = .012) polymorphisms resulted in independent risk factors for AAA. In a multivariable logistic regression analysis adjusted for traditional cardiovascular factors and chronic obstructive pulmonary disease, the prevalence of the contemporary presence of three or four genetic risk conditions was a strong and independent determinant of AAA disease (OR = 2.96, 95% CI 1.67-5.24, P < .0001). For those polymorphisms independently associated with AAA in this study (-1306C/T MMP2, 5A/6A MMP3, -77A/G MMP-13, and G1355A ELN polymorphisms), we performed a meta-analysis of the available data (this paper and literature data). We found a significant association with an increased risk of AAA for MMP3 (AAA patients n = 1258, controls n = 1406: OR = 1.48 [95% CI = 1.23-1.78], I(2) = 0%) and MMP-13 (AAA patients n = 800, controls n = 843: OR = 1.37 [95% CI = 1.04-1.82], I(2) = 25%) polymorphisms and a trend that did not reach the statistical significance, toward a decreased risk of AAA for MMP2 (AAA patients n = 1090, controls n = 1077: OR = 0.83 [95% CI = .60-1.15], I(2) =7 1%) and ELN (AAA patients n = 904, controls n = 1069: OR = 0.79 [95% CI = .53-1.18], I(2) = 72%) polymorphisms.
CONCLUSIONS: These findings suggest that polymorphisms in MMP2, MMP3, MMP-13, and ELN genes may independently contribute to the pathogenesis of AAA.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094117     DOI: 10.1016/j.jvs.2011.07.051

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  20 in total

1.  Genetic risk models: Influence of model size on risk estimates and precision.

Authors:  Ying Shan; Gerard Tromp; Helena Kuivaniemi; Diane T Smelser; Shefali S Verma; Marylyn D Ritchie; James R Elmore; David J Carey; Yvette P Conley; Michael B Gorin; Daniel E Weeks
Journal:  Genet Epidemiol       Date:  2017-02-15       Impact factor: 2.135

2.  Differential Gene Expression in Coiled versus Flow-Diverter-Treated Aneurysms: RNA Sequencing Analysis in a Rabbit Aneurysm Model.

Authors:  A Rouchaud; C Johnson; E Thielen; D Schroeder; Y-H Ding; D Dai; W Brinjikji; J Cebral; D F Kallmes; R Kadirvel
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-31       Impact factor: 3.825

Review 3.  Elastic Fibre Proteins in Elastogenesis and Wound Healing.

Authors:  Xinyang Zhang; Yasmene F Alanazi; Thomas A Jowitt; Alan M Roseman; Clair Baldock
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

4.  Matrix metalloproteinase levels in chronic thoracic aortic dissection.

Authors:  Xiaoming Zhang; Darrell Wu; Justin C Choi; Charles G Minard; Xinguo Hou; Joseph S Coselli; Ying H Shen; Scott A LeMaire
Journal:  J Surg Res       Date:  2014-03-19       Impact factor: 2.192

Review 5.  Expanding Horizons for Abdominal Aortic Aneurysms.

Authors:  Rachel C Rolph; Matthew Waltham; Alberto Smith; Helena Kuivaniemi
Journal:  Aorta (Stamford)       Date:  2015-02-01

6.  MMP-2, TNF-α and NLRP1 polymorphisms in Chinese patients with ankylosing spondylitis and rheumatoid arthritis.

Authors:  Rongbin Sun; Yong Huang; Hui Zhang; Ruiping Liu
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

7.  Investigation of association between genetic polymorphisms of MMP2, MMP8, MMP9 and TIMP2 and development of varicose veins in the Slovak Population - pilot study.

Authors:  J Mazuchová; E Halašová; J Mazuch; M Šarlinová; V Valentová; M Franeková; Š Zelník; K Krkošková; K Javorka; M Péč; M Grendár
Journal:  Physiol Res       Date:  2020-12-31       Impact factor: 1.881

Review 8.  Circular RNA Expression: Its Potential Regulation and Function in Abdominal Aortic Aneurysms.

Authors:  Yanshuo Han; Hao Zhang; Ce Bian; Chen Chen; Simei Tu; Jiahui Guo; Yihao Wu; Dittmar Böckler; Jian Zhang
Journal:  Oxid Med Cell Longev       Date:  2021-06-29       Impact factor: 6.543

Review 9.  Update on abdominal aortic aneurysm research: from clinical to genetic studies.

Authors:  Helena Kuivaniemi; Evan J Ryer; James R Elmore; Irene Hinterseher; Diane T Smelser; Gerard Tromp
Journal:  Scientifica (Cairo)       Date:  2014-04-17

Review 10.  Association of Common Variants in MMPs with Periodontitis Risk.

Authors:  Wenyang Li; Ying Zhu; Pradeep Singh; Deepal Haresh Ajmera; Jinlin Song; Ping Ji
Journal:  Dis Markers       Date:  2016-04-19       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.